1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H2 2020, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.
Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 41 and 21 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 7 and 8 molecules, respectively.
Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionMuscular Dystrophy - Overview
Muscular Dystrophy - Therapeutics Development
Muscular Dystrophy - Therapeutics Assessment
Muscular Dystrophy - Companies Involved in Therapeutics Development
Muscular Dystrophy - Drug Profiles
Muscular Dystrophy - Dormant Projects
Muscular Dystrophy - Discontinued Products
Muscular Dystrophy - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Muscular Dystrophy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by AlloMek Therapeutics, H2 2020
- Muscular Dystrophy - Pipeline by Amicus Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H2 2020
- Muscular Dystrophy - Pipeline by Anima Biotech Inc, H2 2020
- Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H2 2020
- Muscular Dystrophy - Pipeline by ARTHEx Biotech SL, H2 2020
- Muscular Dystrophy - Pipeline by Asklepios BioPharmaceutical Inc, H2 2020
- Muscular Dystrophy - Pipeline by Audentes Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by Avidity Biosciences Inc, H2 2020
- Muscular Dystrophy - Pipeline by Benitec Biopharma Inc, H2 2020
- Muscular Dystrophy - Pipeline by Biophytis SA, H2 2020
- Muscular Dystrophy - Pipeline by Bioprojet SCR, H2 2020
- Muscular Dystrophy - Pipeline by CalyGene Biotechnology Inc, H2 2020
- Muscular Dystrophy - Pipeline by Casma Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H2 2020
- Muscular Dystrophy - Pipeline by Constant Therapeutics LLC, H2 2020
- Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by CRISPR Therapeutics AG, H2 2020
- Muscular Dystrophy - Pipeline by Design Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by Dyne Therapeutics Inc, H2 2020
- Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H2 2020
- Muscular Dystrophy - Pipeline by Elixirgen Therapeutics LLC, H2 2020
- Muscular Dystrophy - Pipeline by Enzerna Biosciences LLC, H2 2020
- Muscular Dystrophy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2020
- Muscular Dystrophy - Pipeline by Expansion Therapeutics Inc, H2 2020
- Muscular Dystrophy - Dormant Projects, H2 2020
- Muscular Dystrophy - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Muscular Dystrophy, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Achelios Therapeutics Inc
- AlloMek Therapeutics
- Amicus Therapeutics Inc
- AMO Pharma Ltd
- Anima Biotech Inc
- Armgo Pharma Inc
- ARTHEx Biotech SL
- Asklepios BioPharmaceutical Inc
- Audentes Therapeutics Inc
- Avidity Biosciences Inc
- Benitec Biopharma Inc
- Biophytis SA
- Bioprojet SCR
- CalyGene Biotechnology Inc
- Casma Therapeutics Inc
- Catabasis Pharmaceuticals Inc
- Constant Therapeutics LLC
- Corcept Therapeutics Inc
- CRISPR Therapeutics AG
- Design Therapeutics Inc
- Dyne Therapeutics Inc
- Edgewise Therapeutics
- Elixirgen Therapeutics LLC
- Enzerna Biosciences LLC
- Exodos Life Sciences Limited Partnership
- Expansion Therapeutics Inc
- Facio Therapies BV
- Fulcrum Therapeutics Inc
- Genea Biocells
- Genzyme Corp
- Keros Therapeutics Inc
- Locana Inc
- ML Bio Solutions Inc
- Modalis Therapeutics Corp
- Myogem Health Company SL
- NeuBase Therapeutics Inc
- Nexien Biopharma Inc
- Oncocross Co Ltd
- Pfizer Inc
- Phrixus Pharmaceuticals Inc
- Prothelia Inc
- Recursion Pharmaceuticals Inc
- Resverlogix Corp
- SanBio Company Limited
- Santhera Pharmaceuticals Holding AG
- Sarcomed AB
- Sarepta Therapeutics Inc
- Seelos Therapeutics, Inc.
- Siwa Therapeutics Inc
- StrideBio Inc
- Syros Pharmaceuticals Inc
- Tamid Bio Inc
- Vertex Pharmaceuticals Inc
- Xonovo Inc
